玻璃體腔內(nèi)注射康柏西普治療視網(wǎng)膜靜脈阻塞繼發(fā)黃斑水腫

秦書艷，沈 磊，力 強(qiáng)

?

·臨床報(bào)告·

玻璃體腔內(nèi)注射康柏西普治療視網(wǎng)膜靜脈阻塞繼發(fā)黃斑水腫

秦書艷，沈 磊，力 強(qiáng)

?METHODS: A total of 22 patients with macular edema secondary to retinal vein occlusion were treated in our hospital during January 2016 to Marth 2016. A total of 22 patients were given three intravitreal injections of Conbercept 0.05mL (0.5mg). Defore and after treatment, best-corrected visual acuity, fundus photography，fundus fluoreseein angiograph(FFA)，optical coherence tomography(OCT)were examined.

?RESULTS: A total of 22 patients were treated with intravitreal injection of Conbercept had different degrees of increase in the mean visual acuity at 1wk, 1, 2 and 3mo. The difference is statistically significant (P<0.05). OCT images show that the thickness of the central retinal thickness of the macular becomes thinner, and the difference is statistically significant (P<0.05). The FFA at 3mo showed a significant reduction in retinal leakage, obvious absorption of retinal hemorrhage.

?CONCLUSION: Intravitreal injection of anti-VEGF drugs Conbercept is an effective way to treat macular edema secondary to retinal vein occlusion, it is worth to promot, but the long-term efficacy and drug injection frequency still need to study further.

目的：觀察玻璃體腔內(nèi)注射康柏西普治療視網(wǎng)膜靜脈阻塞(retinal vein occlusion，RVO)繼發(fā)黃斑水腫的臨床效果及安全性。

方法：回顧性觀察我院2016-01/03間收治的RVO繼發(fā)黃斑水腫的患者22例22眼，3mo內(nèi)給予3次玻璃體腔內(nèi)注射康柏西普0.05mL(0.5mg),比較治療前后患者的視力變化情況，光學(xué)相干斷層掃描(OCT)檢查，眼底熒光造影(FFA)及眼底出血吸收情況。

結(jié)果:所選患者玻璃體內(nèi)注射康柏西普在1wk,1、2、3mo后平均視力均有不同程度的提高，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。OCT圖像顯示黃斑中心凹視網(wǎng)膜厚度明顯變薄，與治療前相比差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后3mo檢查FFA顯示視網(wǎng)膜滲漏明顯減輕，眼底出血明顯吸收。

結(jié)論：玻璃體腔內(nèi)注射抗VEGF藥物康柏西普治療RVO繼發(fā)的黃斑水腫療效肯定，但遠(yuǎn)期療效及注射藥物的頻率尚需進(jìn)一步觀察與探討。

視網(wǎng)膜靜脈阻塞；黃斑水腫； 康柏西普

引用：秦書艷，沈磊，力強(qiáng).玻璃體腔內(nèi)注射康柏西普治療視網(wǎng)膜靜脈阻塞繼發(fā)黃斑水腫.國(guó)際眼科雜志2016;16(12):2329-2331

0引言

視網(wǎng)膜靜脈阻塞(retinal vein occlusion， RVO)的發(fā)病機(jī)制尚不完全明確，多數(shù)學(xué)者認(rèn)為是由于動(dòng)脈供血不足，靜脈壁受損以及異常的血流所致。RVO最常見的類型視網(wǎng)膜分支靜脈阻塞(BRVO),其發(fā)病率0.6%～1.1%,其次是視網(wǎng)膜中央靜脈阻塞(CRVO)，其發(fā)病率0.1%～0.4%[1]。黃斑水腫是其最常見的并發(fā)癥，也是造成視力損害的最重要原因。數(shù)個(gè)多中心的研究結(jié)果表明，抗VEGF治療可顯著減少視網(wǎng)膜層間積液，有利于出血吸收和黃斑水腫的消退[2-3]。本文采用玻璃體腔內(nèi)注射抗VEGF藥物康柏西普治療RVO繼發(fā)黃斑水腫并對(duì)其療效進(jìn)行觀察。

1對(duì)象和方法

1.1對(duì)象 選取2016-01/03在我院門診就診的RVO合并黃斑水腫的患者22例22眼，其中男16例，女6例，年齡36～68歲；……